eIFU management

Compliant.  Controlled.  Convenient.

dokspot is an off-the-shelf eIFU management solution compliant with global eIFU regulations. The product was designed by regulatory experts and software engineers, and provides medical device manufacturers with a controlled and convenient solution to communicating their IFU online.

eIFU Whitepaper

Contact us

MDR 23.1 Compliance

With MDR, medical device manufacturers are required to make available and keep up-to-date any device safety and performance information through their company website. dokspot is a standardized solution that allows manufacturers to successfully and promptly address this requirement.

Global eIFU Compliance

With global eIFU regulations, select manufacturers have the option to ship products without paper IFU. dokspot fulfills all additional eIFU requirements, laying the ground for manufacturers to remove the paper-form IFU, reduce process complexity and mitigate risk.

Controlled

ISO 9001:2015 certified quality management

Validated software with documented releases

Continuously monitored for availability

SSL encryption and integrity protection

Convenient

No development, setup, or infrastructure investment

No technical resources for operation and maintenance

Integrates into website and corporate identity

Expandable to all types of product resources

About us

dokspot is a Swiss based software-as-a-service company focused on eIFU for medical devices. Since 2014, international manufacturers trust dokspot to securely and reliably communicate the IFU of thousands of medical devices through manufacturer-branded eIFU websites.

Learn more

eIFU Whitepaper

Contact us

or visit us at

dokspot.io

dokspot GmbH
Zurich, Switzerland
dokspot.io

Go to article: Home | The triumph of telemedicineGo to article: In This IssueGo to article: BioInteractions Company Insight Go to article: BioInteractions Go to article: ContentsGo to article: ElectroCraft Company InsightGo to article: ElectroCraftGo to article: NewsGo to article: Coronavirus Executive BriefingGo to article: Helbling Go to article: Phosphorus and BioIQ announce partnership for at-home Covid-19 testing kitsGo to article: Roche’s Covid-19 tests could be enough to offset losses during lockdownGo to article: CRISPR biotechnology set to disrupt Covid-19 testing marketGo to article: Resumption of elective surgeries in the US to be short-livedGo to article: Abbott’s ID NOW Covid-19 test under questionGo to article: Sandvik Company InsightGo to article: Sandvik Go to article: The medical industry briefingGo to article: Mus musculus: how nanofluidic drug delivery could counter muscle loss in spaceGo to article: Coding in medtech: setting standards for the digital ageGo to article: SartoriusGo to article: Will digital mental health solutions thrive after Covid-19?Go to article: South Korea: the rise of a new medtech giant? Go to article: ICF MercantileGo to article: Is there a bright future for telemedicine in a post-Covid world?Go to article: PSN LabsGo to article: Q&A: discussing cancer blood testing tech with VolitionGo to article: dokspotGo to article: What does the MDR delay mean for the European medtech sector?Go to article: Covid-19 immunity passports: how to protect health dataGo to article: The key list powered by GlobalDataGo to article: Deals in brief powered by GlobalDataGo to article: TS Quality & EngineeringGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2 ) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next Issue